ISSN: 0973-7510

E-ISSN: 2581-690X

Research Article | Open Access
Hasan Faisal Hussein Kahya1 and Mohammed Taha Mahmood2
1Department of Biology, College of Education for Pure Sciences, University of Mosul, Mosul, Iraq.
2Department of Basic Sciences, College of Nursing, University of Mosul, Mosul, Iraq.
J Pure Appl Microbiol. 2022;16(1):167-173 | Article Number: 7332 | © The Author(s). 2022
Issue online: March 2022

The pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) has become the most dangerous viral infection worldwide. Since its identification in late 2019, the number of medical trials to combat the infection has sharply increased. Here, we investigated the profiles of IgG and IgM in 85 patients with confirmed SARS-CoV-2 infection from day 1 after symptom onset until day 35 with 5-day intervals. Serum samples were collected and stored until use. We observed that IgM levels were detectable on day 5 post symptom onset and increased sharply, with the highest rate detected in moderate cases (32.332 ± 4.32, n=10). Subsequently, a significant reduction in IgM was observed until it was undetectable on day 35 after symptom onset. Meanwhile, IgG levels were detected on day 10 post symptom onset, and the highest rate was observed in moderate cases (8.232 ± 2.3, n=10). A significant increase in IgG rate was observed in all patients, with the highest rate in moderate cases (42.432 ± 4.34, n=67) on day 35 post symptom onset. The statistical difference between the case and control groups was significant (p≤0.001). Two out of 85 patients died during the study.


SARS-COV-2, COVID-19, Serologic response, IgG, IgM

Article Metrics

Article View: 67

Share This Article

© The Author(s) 2022. Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License which permits unrestricted use, sharing, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.